These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 22639843)

  • 1. Long-term survival in patients with clear cell adenocarcinoma of ovary treated with irinotecan hydrochloride plus cisplatin therapy as first-line chemotherapy.
    Kunito S; Takakura S; Nagata C; Saito M; Yanaihara N; Yamada K; Okamoto A; Sasaki H; Ochiai K; Tanaka T
    J Obstet Gynaecol Res; 2012 Dec; 38(12):1367-75. PubMed ID: 22639843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant chemotherapy with irinotecan hydrochloride and cisplatin for clear cell carcinoma of the ovary.
    Takano M; Kikuchi Y; Yaegashi N; Suzuki M; Tsuda H; Sagae S; Udagawa Y; Kuzuya K; Kigawa J; Takeuchi S; Tsuda H; Moriya T; Sugiyama T
    Oncol Rep; 2006 Dec; 16(6):1301-6. PubMed ID: 17089053
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progression-free survival and overall survival of patients with clear cell carcinoma of the ovary treated with paclitaxel-carboplatin or irinotecan-cisplatin: retrospective analysis.
    Takano M; Sugiyama T; Yaegashi N; Suzuki M; Tsuda H; Sagae S; Udagawa Y; Kuzuya K; Kigawa J; Takeuchi S; Tsuda H; Moriya T; Kikuchi Y
    Int J Clin Oncol; 2007 Aug; 12(4):256-60. PubMed ID: 17701003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized phase II trial of paclitaxel plus carboplatin therapy versus irinotecan plus cisplatin therapy as first-line chemotherapy for clear cell adenocarcinoma of the ovary: a JGOG study.
    Takakura S; Takano M; Takahashi F; Saito T; Aoki D; Inaba N; Noda K; Sugiyama T; Ochiai K;
    Int J Gynecol Cancer; 2010 Feb; 20(2):240-7. PubMed ID: 20169667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized Phase III Trial of Irinotecan Plus Cisplatin Compared With Paclitaxel Plus Carboplatin As First-Line Chemotherapy for Ovarian Clear Cell Carcinoma: JGOG3017/GCIG Trial.
    Sugiyama T; Okamoto A; Enomoto T; Hamano T; Aotani E; Terao Y; Suzuki N; Mikami M; Yaegashi N; Kato K; Yoshikawa H; Yokoyama Y; Tanabe H; Nishino K; Nomura H; Kim JW; Kim BG; Pignata S; Alexandre J; Green J; Isonishi S; Terauchi F; Fujiwara K; Aoki D
    J Clin Oncol; 2016 Aug; 34(24):2881-7. PubMed ID: 27400948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of surgical staging in stage I clear cell adenocarcinoma of the ovary.
    Suzuki K; Takakura S; Saito M; Morikawa A; Suzuki J; Takahashi K; Nagata C; Yanaihara N; Tanabe H; Okamoto A
    Int J Gynecol Cancer; 2014 Sep; 24(7):1181-9. PubMed ID: 25010038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Irinotecan hydrochloride (CPT-11) and cisplatin as first-line chemotherapy after initial surgery for ovarian clear cell adenocarcinoma.
    Takakura S; Saito M; Ueda K; Motegi M; Takao M; Yamada K; Okamoto A; Niimi S; Sasaki H; Tanaka T; Ochiai K
    Int Surg; 2007; 92(4):202-8. PubMed ID: 18050828
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Irinotecan hydrochloride (CPT-11) and mitomycin C as the first line chemotherapy for ovarian clear cell adenocarcinoma.
    Nishino K; Aoki Y; Amikura T; Obata H; Sekine M; Yahata T; Fujita K; Tanaka K
    Gynecol Oncol; 2005 Jun; 97(3):893-7. PubMed ID: 15894369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant chemotherapy for stage I clear cell carcinoma of the ovary: an analysis of fully staged patients.
    Takada T; Iwase H; Iitsuka C; Nomura H; Sakamoto K; Omatsu K; Takeshima N; Takizawa K
    Int J Gynecol Cancer; 2012 May; 22(4):573-8. PubMed ID: 22398705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [A case of brain metastasis from advanced ovarian clear-cell carcinoma during maintenance chemotherapy with irinotecan+cisplatin].
    Takami M; Kita E; Kuwana Y; Ohta Y; Nakayama Y; Fukai H; Matsumoto H; Takimoto T; Ichikawa G; Yamamoto T
    Gan To Kagaku Ryoho; 2008 Jul; 35(7):1243-5. PubMed ID: 18633273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival impact of adjuvant paclitaxel and carboplatin for early-stage ovarian clear-cell carcinoma with complete surgical staging.
    Kajiyama H; Shibata K; Suzuki S; Ino K; Kawai M; Nagasaka T; Nawa A; Kikkawa F
    Gynecol Obstet Invest; 2011; 72(4):252-6. PubMed ID: 22041903
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II study of combination chemotherapy using docetaxel and irinotecan for TC-refractory or TC-resistant ovarian carcinomas (GOGO-OV2 study) and for primary clear or mucinous ovarian carcinomas (GOGO-OV3 Study).
    Ueda Y; Miyatake T; Nagamatsu M; Yamasaki M; Nishio Y; Yoshino K; Fujita M; Tsutsui T; Enomoto T; Kimura T
    Eur J Obstet Gynecol Reprod Biol; 2013 Sep; 170(1):259-63. PubMed ID: 23880598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival impact of capsule rupture in stage I clear cell carcinoma of the ovary in comparison with other histological types.
    Higashi M; Kajiyama H; Shibata K; Mizuno M; Mizuno K; Hosono S; Kawai M; Nakanishi T; Nagasaka T; Kikkawa F
    Gynecol Oncol; 2011 Dec; 123(3):474-8. PubMed ID: 21955484
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploratory study of effective chemotherapy to clear cell carcinoma of the ovary.
    Kita T; Kikuchi Y; Kudoh K; Takano M; Goto T; Hirata J; Tode T; Nagata I
    Oncol Rep; 2000; 7(2):327-31. PubMed ID: 10671681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Less impact of adjuvant chemotherapy for stage I clear cell carcinoma of the ovary: a retrospective Japan Clear Cell Carcinoma Study.
    Takano M; Sugiyama T; Yaegashi N; Sagae S; Kuzuya K; Udagawa Y; Tsuda H; Suzuki M; Kigawa J; Goto T; Tsuda H; Moriya T; Kikuchi Y
    Int J Gynecol Cancer; 2010 Dec; 20(9):1506-10. PubMed ID: 21119366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low response rate of second-line chemotherapy for recurrent or refractory clear cell carcinoma of the ovary: a retrospective Japan Clear Cell Carcinoma Study.
    Takano M; Sugiyama T; Yaegashi N; Sakuma M; Suzuki M; Saga Y; Kuzuya K; Kigawa J; Shimada M; Tsuda H; Moriya T; Yoshizaki A; Kita T; Kikuchi Y
    Int J Gynecol Cancer; 2008; 18(5):937-42. PubMed ID: 18081792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Successful optimal debulking surgery following chemotherapy combined with irinotecan hydrochloride and cisplatin for advanced clear cell carcinoma of the ovary].
    Hirakawa H; Futagami M; Yokoyama Y; Hakamada K; Mizunuma H
    Gan To Kagaku Ryoho; 2011 May; 38(5):857-60. PubMed ID: 21566454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Prognostic analysis of 88 patients with ovarian clear cell carcinoma].
    Ma SK; Zhang HT; Wu LY; Liu LY
    Zhonghua Zhong Liu Za Zhi; 2007 Oct; 29(10):784-8. PubMed ID: 18396695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience.
    Pectasides D; Fountzilas G; Aravantinos G; Kalofonos C; Efstathiou H; Farmakis D; Skarlos D; Pavlidis N; Economopoulos T; Dimopoulos MA
    Gynecol Oncol; 2006 Aug; 102(2):285-91. PubMed ID: 16516283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy.
    Sugiyama T; Kamura T; Kigawa J; Terakawa N; Kikuchi Y; Kita T; Suzuki M; Sato I; Taguchi K
    Cancer; 2000 Jun; 88(11):2584-9. PubMed ID: 10861437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.